Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.

Eli Lilly has ascended to the pinnacle of the pharmaceutical industry, claiming the top spot in the prestigious Pharma 50 ranking for fiscal year 2025. This remarkable leap from ninth position just a year prior underscores a dramatic shift in the sector, largely driven by the explosive growth of its incretin therapies. However, the pharma sector is notorious for its revolving door at the top, and the immediate question facing Lilly is the sustainability of its newly acquired leadership. The margin separating Lilly from its closest competitor, Merck & Co., is razor-thin, with Lilly reporting $65.18 billion in pharmaceutical revenue against Merck’s $65.01 billion for FY2025 – a mere $170 million difference. This tight race highlights the intense competitive pressures and the transformative power of innovation in the global drug market.

The New Pharma King: Lilly’s Unprecedented Ascent

Lilly’s rapid rise is a testament to its audacious strategy and flawless execution in a fiercely competitive therapeutic area. Chairman and CEO Dave Ricks, reflecting on the company’s unprecedented trajectory in Q4 2025, articulated a vision that challenges traditional pharmaceutical business models. He noted the exceptional phenomenon of a large patient population paying out-of-pocket for prescription medication, stating, "I am hard pressed to think of an analog where you have this many people paying out of pocket for prescription medication. I don’t think there’s a good analog in our industry." This observation underpins Lilly’s innovative approach, which includes leveraging first-party data, exploring subscription pricing models, and building a consumer-centric platform designed to minimize patient friction in accessing treatment.

Lilly’s FY2025 revenue of $65.18 billion represents an astonishing 45% increase year-over-year, a surge almost entirely attributable to volume growth in its incretin franchise. This was achieved despite absorbing a 6% global price headwind, demonstrating the sheer demand for its therapies. The tirzepatide franchise, encompassing Mounjaro (for type 2 diabetes) and Zepbound (for obesity), generated a combined $36.5 billion, making it the highest-grossing drug franchise across the entire industry. In Q3 alone, these drugs topped $10 billion in sales, officially surpassing Merck’s venerable cancer blockbuster, Keytruda, as the world’s best-selling drug. This commercial triumph marks a significant milestone, repositioning Lilly from a diversified pharmaceutical player to a dominant force primarily powered by metabolic health innovation.

Lilly’s Strategic Masterstroke: The Incretin Revolution

Lilly’s strategic ascent can be distilled into three critical pillars, each executed with precision and foresight, effectively countering Novo Nordisk’s initial lead in the incretin market:

The Superior Molecule: Tirzepatide’s Clinical Edge:
In 2023, Novo Nordisk’s strategy revolved around leveraging semaglutide (Ozempic for diabetes, approved 2017; Wegovy for obesity, approved 2021) to capture the vast metabolic health market. By the time Lilly’s Zepbound received its obesity approval in late 2023, Novo enjoyed a two-year head start, significant cultural momentum from the "Ozempic era," and a semaglutide franchise already generating tens of billions in revenue.
However, Lilly’s tirzepatide proved to be a formidable challenger due to its pharmacological profile. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormonal pathways involved in glucose metabolism and appetite regulation, whereas semaglutide primarily targets one (GLP-1). This dual action translated into superior clinical outcomes. The SURMOUNT-5 trial, the first head-to-head obesity trial comparing the two drugs, definitively showed tirzepatide’s advantage: a mean weight loss of 20.2% versus 13.7% for semaglutide at 72 weeks. This statistically significant difference resonated powerfully with prescribers and patients alike. By mid-2025, Lilly’s tirzepatide drugs accounted for an impressive two-thirds of all patients on obesity medications in the U.S., a rapid market penetration that underscored the molecule’s efficacy and patient preference. The clinical superiority was a game-changer, establishing tirzepatide as the gold standard in a burgeoning therapeutic category.
Aggressive Manufacturing Scale-Up and Supply Chain Resilience:
A critical factor in Lilly’s success was its proactive and aggressive investment in manufacturing capacity. Throughout 2023 and 2024, Novo Nordisk struggled to meet the skyrocketing global demand for semaglutide, leading to its inclusion on the FDA’s drug shortage list. This shortage created a vacuum, partially filled by compounding pharmacies, which posed risks to patient safety and diverted market share. While Lilly also faced initial supply constraints, it invested earlier and more substantially in expanding its production capabilities. By mid-2025, CEO Dave Ricks reported a staggering increase, stating that Lilly had "produced more than 1.6 times the amount of salable incretin doses during the first half of 2025 compared to the first half of 2024."
Lilly’s commitment to supply resilience continues, with significant ongoing investments. The company is actively constructing additional manufacturing sites and, in January, announced a massive $55 billion domestic investment at the J.P. Morgan Healthcare Conference. This strategic outlay serves multiple purposes: ensuring uninterrupted supply to meet burgeoning demand, hedging against potential tariffs, and preventing any future erosion of market share to compounders. This commitment to robust supply chain management was crucial in translating clinical superiority into market dominance.
The Consumer Pivot: LillyDirect and Frictionless Access:
Lilly revolutionized its commercial strategy by building LillyDirect, a scaled direct-to-consumer (DTC) platform. This innovative approach allows patients to discover, initiate, and consistently adhere to treatment without navigating the often-complex traditional pharmacy and insurance systems. Ilya Jungerman, Lilly’s chief commercial officer, described LillyDirect as an effort to "reduce consumer friction," adopting language typically found in the tech sector rather than traditional pharma.
The out-of-pocket market for incretin prescriptions has grown significantly, and Lilly strategically structured its pricing and distribution channels to capture this segment like no pharmaceutical company before. LillyDirect provides a streamlined pathway for patients, offering access to telehealth providers, pharmacy services, and direct medication delivery. This move directly addresses the challenges patients face with insurance coverage, prior authorizations, and pharmacy stock issues, particularly for novel and expensive therapies. By owning the patient journey from prescription to delivery, Lilly not only captured a substantial portion of the cash-paying market but also gathered invaluable first-party data, enabling more personalized engagement and service improvements. This bold pivot to a consumer-centric model represents a paradigm shift in pharmaceutical commercialization.

Novo Nordisk’s Tumultuous Fall from Grace

While Lilly was executing its multi-pronged strategy, Novo Nordisk, the erstwhile leader in the incretin space, experienced a cascade of setbacks that significantly eroded its market position and investor confidence. At the time of this report, Novo Nordisk’s stock was trading at $35.29 per share, nearly 50% lower than its valuation a year prior, reflecting a dramatic unraveling that began in late 2024.

The primary catalyst for Novo’s downturn was the disappointing performance of CagriSema, its highly anticipated next-generation obesity drug, which was positioned as its answer to Zepbound.

December 2024: Results from the Phase III REDEFINE 1 trial were announced. CagriSema, a combination of semaglutide and cagrilintide, missed its ambitious 25% weight-loss target, achieving 22.7%. The market reacted swiftly and harshly, with Novo Nordisk’s stock plummeting approximately 20% in a single day, wiping out an estimated €90 billion in market value.
March 2025: A second pivotal CagriSema trial fell even further short, showing only 15.7% weight loss in patients with Type 2 diabetes. This further dampened investor enthusiasm and raised serious questions about the drug’s competitive viability.
February 2026: The definitive blow came with the head-to-head REDEFINE 4 trial. CagriSema achieved 23% weight loss at 84 weeks, failing to demonstrate noninferiority to tirzepatide, which achieved 25.5%. This trial result solidified tirzepatide’s clinical superiority and CagriSema’s inability to compete effectively in the increasingly competitive obesity market.

The corporate turmoil that ensued at Novo Nordisk was profound.

May 2025: CEO Lars Fruergaard Jørgensen was ousted, marking a significant leadership change in the wake of the trial failures and market value erosion.
Late July 2025: Mike Doustdar was named as the new CEO, officially taking over on August 7.
September 2025: Barely a month into his tenure, Doustdar announced a staggering 9,000 layoffs, representing 11% of Novo Nordisk’s global workforce. This included 5,000 employees in Denmark, making it one of the largest corporate layoffs in the country’s history. This move sent shockwaves through Denmark, a nation where Novo Nordisk’s ecosystem had become a cornerstone of the economy. At its peak in mid-2024, Novo Nordisk’s market capitalization of $570 billion had actually exceeded Denmark’s entire GDP, with the company accounting for roughly 40% of the country’s exports and nearly half its GDP growth. The layoffs underscored the severe financial pressure and strategic recalibration forced upon the company.
October 2025: The boardroom itself experienced a significant shake-up. Chairman Helge Lund and more than half the board members stepped down following a dispute with the Novo Nordisk Foundation, the company’s major shareholder, over the pace and direction of strategic changes. Lars Rebien Sørensen, former CEO (2000-2016) and current chair of the Foundation, was installed as the new board chair, effectively completing a Foundation-led takeover to stabilize the company and steer its future. Over $450 billion in market value had been erased in approximately 18 months, a stark illustration of the consequences of strategic missteps and competitive pressures.

The financial contrast between Lilly and Novo Nordisk for FY2025 is stark. While Lilly surged with a 45% revenue increase, Novo Nordisk reported approximately $46.8 billion in FY2025 revenue, with 10% growth at constant exchange rates. While respectable in absolute terms, this growth was dwarfed by Lilly’s explosive performance. Furthermore, Novo Nordisk guided for a 2026 sales decline of 5% to 13%, marking its first projected revenue contraction in nearly a decade. In contrast, Lilly projected robust revenue growth of 23% to 27% for 2026, signaling continued momentum.

The Broader Market Dynamics and Future Challenges

Despite Lilly’s triumphant rise, the pharmaceutical market remains dynamic, and challenges are already emerging, hinting at the inherent volatility of industry leadership. The rapid expansion of the U.S. incretin analogs market, while still significant, showed signs of deceleration in Q4 2025, growing by 33% compared to the exponential rates observed in 2023 and early 2024. Lilly’s U.S. market share for incretins reached 60.5% against Novo Nordisk’s 39.1%, yet the overall market’s expansion rate is moderating as supply begins to catch up with demand.

Moreover, the "price headwind" faced by Lilly is expected to intensify. CFO Lucas Montarce informed analysts that net price erosion in 2026 is projected to accelerate to the "low to mid-teens" percentage, a sharp increase from the 6% absorbed in 2025. This acceleration is driven by several factors:

Most-Favored-Nation (MFN) Pricing: Policies like MFN pricing, often negotiated by governments (such as the Trump administration mentioned), aim to lower drug costs by requiring pharmaceutical companies to offer prices no higher than those in other developed countries. This puts downward pressure on U.S. prices.
Expanded Direct-to-Consumer (DTC) Discounting: While LillyDirect has been a success, the strategic use of direct-to-consumer discounting to attract and retain patients in the out-of-pocket market inherently reduces the net price per dose. As competition increases and market saturation looms, such discounting may become more pervasive.
Payer Pressure: As GLP-1 drugs become more widespread, health insurers and national healthcare systems are increasingly scrutinizing their high costs, pushing for greater rebates and discounts.

This deceleration in market growth and escalating pricing pressure has not gone unnoticed by investors. In early 2026, Lilly’s stock has shown a downward trend, down approximately 8% year-to-date. This contrasts with competitors like Merck and Pfizer, which have been trading near their 52-week highs. The market, while acknowledging Lilly’s revenue leadership, appears to be immediately pricing in the risks associated with potential GLP-1 market deceleration and increased competition. This tension—revenue dominance on one side, investor skepticism about its durability on the other—forms the central narrative of this year’s Pharma 50.

Implications for the Pharmaceutical Landscape

Lilly’s ascent and Novo Nordisk’s stumble carry profound implications for the broader pharmaceutical industry:

The Power of Innovation and Efficacy: The success of tirzepatide underscores that superior clinical efficacy remains the most potent driver of market share, even against established first-movers. This will likely spur further investment in novel mechanisms of action for chronic diseases.
Manufacturing as a Strategic Differentiator: The supply chain issues faced by Novo Nordisk and Lilly’s aggressive investment demonstrate that manufacturing capacity is no longer just an operational concern but a critical strategic advantage that can make or break a product launch and sustained market presence. Companies will need to prioritize robust, scalable manufacturing from early development.
The Rise of Direct-to-Consumer Models: LillyDirect signals a potential paradigm shift in pharmaceutical commercialization. As patient out-of-pocket costs rise and digital health solutions proliferate, more companies may explore hybrid or fully DTC models, challenging the traditional intermediary-heavy distribution networks. This also necessitates new capabilities in data analytics, customer service, and digital engagement.
Chronic Disease Management Transformation: The incretin revolution is reshaping the approach to metabolic health. Beyond diabetes and obesity, the potential for these drugs in areas like cardiovascular disease, kidney disease, and even neurological conditions (as research continues) could fundamentally alter treatment paradigms and disease progression for millions. This will also place immense pressure on healthcare systems to adapt to the cost and scale of these therapies.
Increased Scrutiny on Drug Pricing: The high cost of GLP-1s, coupled with their widespread use, will inevitably intensify public and political scrutiny on drug pricing. Companies will face ongoing pressure to demonstrate value and offer access solutions, potentially leading to more complex pricing structures and government interventions.
Consolidation and M&A: The rapid value creation and destruction witnessed could spur further consolidation. Companies with strong pipelines in emerging areas, or those looking to acquire manufacturing capabilities or innovative commercial platforms, may become attractive targets or acquirers.

The Race Ahead: Sustainability of Leadership

Lilly’s journey to the top of the Pharma 50 is a compelling narrative of innovation, strategic execution, and market disruption. However, history suggests that holding the top spot in the pharmaceutical industry is an arduous task. The immediate future for Lilly will involve navigating increasing competitive pressures, managing price erosion, and continually innovating to maintain its edge. The market’s immediate reaction, signaling skepticism about the durability of its GLP-1-driven growth, underscores the constant challenge. Whether Lilly can defy historical precedent and establish a sustained reign at the summit of the pharmaceutical world remains the central and most intriguing question for the coming years.

Pharma 50: Top Companies by FY2025 Revenue

Rank	Company	Headquarters	FY2025 Revenue (USD)
1	Eli Lilly	USA	$65.18B
2	Merck & Co.	USA	$65.01B
3	Pfizer Inc.	USA	$62.58B
4	AbbVie	USA	$61.16B
5	Johnson & Johnson	USA	$60.40B
6	AstraZeneca plc	UK	$58.74B
7	Roche Group	Switzerland	$57.40B
8	Novartis AG	Switzerland	$56.67B
9	Sanofi S.A.	France	$52.73B
10	Bristol Myers Squibb	USA	$48.20B
11	Novo Nordisk	Denmark	$46.71B
12	GSK plc	UK	$43.04B
13	Amgen	USA	$36.75B
14	Boehringer Ingelheim	Germany	$31.38B
15	Takeda Pharmaceutical	Japan	$30.62B
16	Gilead Sciences	USA	$29.44B
17	Bayer	Germany	$20.12B
18	Teva Pharmaceutical	Israel	$17.26B
19	CSL Limited	Australia	$15.56B
20	Regeneron	USA	$14.34B
21	Viatris	USA	$14.30B
22	Astellas Pharma	Japan	$12.78B
23	Daiichi Sankyo	Japan	$12.61B
24	Vertex Pharmaceuticals	USA	$12.00B
25	Sandoz Group	Switzerland	$11.16B
26	Otsuka Holdings	Japan	$10.89B
27	Bausch Health	Canada	$10.27B
28	Biogen	USA	$9.89B
29	Merck KGaA	Germany	$9.71B
30	UCB	Belgium	$8.74B
31	Grifols	Spain	$8.49B
32	Chugai Pharmaceutical	Japan	$8.41B
33	Servier	France	$7.74B
34	Organon	USA	$6.22B
35	Sun Pharmaceutical	India	$5.97B
36	Abbott Laboratories	USA	$5.54B
37	Menarini	Italy	$5.52B
38	Eisai	Japan	$5.28B
39	Incyte	USA	$5.14B
40	STADA Arzneimittel	Germany	$4.85B
41	Sino Biopharmaceutical	China	$4.46B
42	Jiangsu Hengrui	China	$4.44B
43	Ipsen	France	$4.43B
44	Jazz Pharmaceuticals	Ireland	$4.27B
45	Perrigo	Ireland	$4.25B
46	Chiesi Farmaceutici*	Italy	$3.85B*
47	Dr. Reddy’s	India	$3.74B
48	H. Lundbeck	Denmark	$3.72B
49	Shanghai Pharmaceutical*	China	$3.50B*
50	Kyowa Kirin	Japan	$3.32B

*Estimate. FY2025 results not yet reported; figure based on most recent available data.
Revenue reflects pharmaceutical divisions only where applicable. All non-USD figures converted at IRS annual average exchange rates.

Note on Methodology: The Pharma 50 ranks companies by pharmaceutical revenue, excluding non-pharma divisions. Johnson & Johnson, for example, reported $94.2 billion in total 2025 sales across its broader business, but only its Innovative Medicine division ($60.40 billion) is counted here. This is consistent with Nature/Evaluate’s approach, which separately ranked Lilly No. 1 by 2025 prescription-drug sales.